While investors have long treated the pharmaceuticals’ industry with caution, those that avoid the sector are missing out on clear opportunities. While navigating the fast-developing industry is not ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 ...